Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL14853938 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056533 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL329746 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL10815678 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056827 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9060684 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL375985 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL7752140 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1804774 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | claimed |
| US-12496466-B2 | Simulation-based drug treatment planning | INSIGHTEC LTD. (IL) | 2025-12-16 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | HELIX NANOTECHNOLOGIES INC | 2025-08-28 | — | — | US | claimed |
| EP-3630985-B1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS INC (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4606903-A1 | METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION | Asymchem Life Science (Tianjin) Co., Ltd (CN) | 2025-08-27 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-1612213-A1 | PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUOROURIDINE | Central Glass Company, Limited (JP) | 2006-01-04 | — | — | EP | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| US-4371613-A | TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC28A1 28/4885SLC28A2 34/4885SLC29A1 18/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC28A1 28/4885SLC28A2 34/4885SLC29A1 18/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | SLC28A1 1537/4885SLC28A2 1869/4885SLC29A1 1862/4885 |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | SLC28A1 3845/4885SLC28A2 3161/4885SLC29A1 3727/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC28A1 21/4885SLC28A2 33/4885SLC29A1 19/4885 |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | C1QBP, SSB, SARNP | SLC28A1 991/4885SLC28A2 1151/4885SLC29A1 949/4885 |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | RNGTT, RNMT, NSUN3 | SLC28A1 684/4885SLC28A2 654/4885SLC29A1 799/4885 |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | SLC28A1 2912/4885SLC28A2 3579/4885SLC29A1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.